cefazolin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	530	25953-19-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefazolin cefazolin sodium cefamezin cefaprim cefazoline cephamezine cephazolin cephazoline cefazolin sodium salt	A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Molecular weight: 454.50 Formula: C14H14N8O4S3 CLOGP: -0.64 LIPINSKI: 1 HAC: 12 HDO: 2 TPSA: 156.09 ALOGS: -2.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefazolin
cefazolin sodium
cefamezin
cefaprim
cefazoline
cephamezine
cephazolin
cephazoline
cefazolin sodium salt

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Molecular weight: 454.50
Formula: C14H14N8O4S3
CLOGP: -0.64
LIPINSKI: 1
HAC: 12
HDO: 2
TPSA: 156.09
ALOGS: -2.97
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	80 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	33 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	146.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.89 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.18 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.12 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Oct. 4, 1973	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	604.84	13.98	226	15660	23407	63449729
Anaphylactic reaction	279.14	13.98	185	15701	65915	63407221
Hypotension	196.57	13.98	288	15598	272316	63200820
Acute generalised exanthematous pustulosis	178.45	13.98	76	15810	11023	63462113
Arthrodesis	155.65	13.98	48	15838	2753	63470383
Postoperative wound infection	115.93	13.98	56	15830	10869	63462267
Fatigue	95.60	13.98	52	15834	887976	62585160
Bronchospasm	91.84	13.98	56	15830	17224	63455912
Erythema	83.37	13.98	154	15732	175597	63297539
Type I hypersensitivity	81.99	13.98	30	15856	2912	63470224

Showing 1 to 10 of 159 entries

Previous1 2 3 4 5…16Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	391.99	14.89	169	13831	15772	34927159
Anaphylactic reaction	273.97	14.89	167	13833	32134	34910797
Hypoprothrombinaemia	160.79	14.89	36	13964	346	34942585
Kounis syndrome	97.35	14.89	37	13963	2481	34940450
Fear	96.01	14.89	57	13943	10419	34932512
Drug reaction with eosinophilia and systemic symptoms	82.87	14.89	83	13917	32929	34910002
Thymus hypoplasia	80.65	14.89	21	13979	397	34942534
Lymphoid tissue hypoplasia	80.65	14.89	21	13979	397	34942534
Hypotension	79.42	14.89	231	13769	221418	34721513
Renal injury	75.14	14.89	50	13950	11145	34931786

Showing 1 to 10 of 124 entries

Previous1 2 3 4 5…13Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	945.96	13.04	384	27324	35612	79681068
Anaphylactic reaction	499.69	13.04	329	27379	83414	79633266
Hypotension	246.10	13.04	499	27209	439818	79276862
Acute generalised exanthematous pustulosis	236.85	13.04	117	27591	17137	79699543
Hypoprothrombinaemia	208.42	13.04	49	27659	693	79715987
Kounis syndrome	148.71	13.04	56	27652	4226	79712454
Bronchospasm	136.78	13.04	93	27615	24766	79691914
Fatigue	124.25	13.04	86	27622	929641	78787039
Urticaria	118.96	13.04	223	27485	184978	79531702
Fear	117.99	13.04	81	27627	21905	79694775

Showing 1 to 10 of 255 entries

Previous1 2 3 4 5…26Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DB04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Pneumonia due to Streptococcus	indication	34020007
Lower respiratory tract infection	indication	50417007
Bacterial pneumonia	indication	53084003	DOID:874
Cholangitis	indication	82403002	DOID:9446
Infection of bone	indication	111253001
Bacterial endocarditis	indication	301183007
Bacterial urinary infection	indication	312124009

Showing 1 to 10 of 19 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.22	acidic
pKa2	12.21	acidic
pKa3	1.52	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 1GM BASE/VIAL	CEFAZOLIN AND DEXTROSE	B BRAUN	N050779	July 27, 2000	RX	INJECTABLE	INJECTION	Nov. 23, 2023	NEW PATIENT POPULATION
EQ 2GM BASE/VIAL	CEFAZOLIN AND DEXTROSE	B BRAUN	N050779	Jan. 13, 2012	RX	INJECTABLE	INJECTION	Nov. 23, 2023	NEW PATIENT POPULATION
EQ 500MG BASE/VIAL	CEFAZOLIN AND DEXTROSE	B BRAUN	N050779	July 27, 2000	DISCN	INJECTABLE	INJECTION	Nov. 23, 2023	NEW PATIENT POPULATION

Showing 1 to 3 of 3 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE					WOMBAT-PK

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
002720	NDDF
004841	NDDF
10935	IUPHAR_LIGAND_ID
203171	RXNORM
27164-46-1	SECONDARY_CAS_RN
2991	INN_ID
33255	PUBCHEM_CID
35509	MMSL
387470007	SNOMEDCT_US
4017460	VANDF

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9139	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAVENOUS	NDA	28 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9140	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	28 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9261	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9262	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9262	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9665	INJECTION, POWDER, FOR SOLUTION	20 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9923	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9923	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9924	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9924	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next